Monte Rosa Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Monte Rosa Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boston
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- GLUE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001826457
Board of directors
-
Alexander Mayweg · DirectorSince 2023
- Since 2023
-
Andrew N. Schiff · DirectorSince 2023
-
Anthony M. Manning · DirectorSince 2023
-
Chandra P. Leo · DirectorSince 2025
-
Christine Siu · DirectorSince 2023
-
Eric A. Hughes · DirectorSince 2024
-
Jan Skvarka · DirectorSince 2023
-
Kimberly Blackwell · DirectorSince 2023
-
Markus Warmuth · Director · President & CEOSince 2023
Chief executives
Markus Warmuth
· President & CEO
Dates unknown
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
79.0%
-
99.0%
-
99.1%
Board connections
6 of this board's directors also sit on 10 other boards.
- via Alexander Mayweg and Ali Behbahani
- via Jan Skvarka and Kimberly Blackwell
- via Andrew N. Schiff
- via Ali Behbahani
- via Ali Behbahani
- via Kimberly Blackwell
- via Ali Behbahani
- via Ali Behbahani
- via Anthony M. Manning
- via Ali Behbahani
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $4,111,207
- 36 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 16, 2026 | Markus Warmuth Director, Officer (President & CEO) | Open-market sale | −9,500 | $23.18 | $220,219 |
| Jul 15, 2026 | Champoux Jennifer Officer (Chief Operating Officer) | Option exercise | +4,351 | $3.98 | $17,317 |
| Jul 15, 2026 | Champoux Jennifer Officer (Chief Operating Officer) | Open-market sale | −4,351 | $23.38 | $101,730 |
| Jul 6, 2026 | Townson Sharon Officer (Chief Scientific Officer) | Option exercise | +6,000 | $6.14 | $36,840 |
| Jul 6, 2026 | Townson Sharon Officer (Chief Scientific Officer) | Open-market sale | −5,600 | $23.25 | $130,197 |
| Jul 6, 2026 | Townson Sharon Officer (Chief Scientific Officer) | Open-market sale | −400 | $24.13 | $9,652 |
| Jul 1, 2026 | Ali Behbahani Director | Other | −1,000,000 | — | — |
| Jul 1, 2026 | Ali Behbahani Director | Other | +15,000 | — | — |
| Jul 1, 2026 | Ali Behbahani Director | Other | −15,000 | — | — |
| Jun 30, 2026 | Janku Filip Officer (Chief Medical Officer) | Option exercise | +5,407 | $13.41 | $72,508 |
| Jun 30, 2026 | Janku Filip Officer (Chief Medical Officer) | Open-market sale | −5,407 | $24.50 | $132,472 |
| Jun 29, 2026 | Janku Filip Officer (Chief Medical Officer) | Option exercise | +6,000 | $7.56 | $45,360 |
| Jun 29, 2026 | Anthony M. Manning Director | Option exercise | +10,000 | $4.16 | $41,600 |
| Jun 29, 2026 | Janku Filip Officer (Chief Medical Officer) | Open-market sale | −6,000 | $22.95 | $137,700 |
| Jun 29, 2026 | Anthony M. Manning Director | Open-market sale | −10,000 | $23.11 | $231,100 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.